Ramaco Resources Announces Second Quarter Class A Stock Dividend Details
LEXINGTON, Ky., June 2, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB, "Ramaco" or the "Company") a leading operator and developer of high-quality, low-cost metallurgical coal in Central Appalachia and future developer of rare earth elements and critical minerals in Wyoming, today announced the dividend ratio of its previously declared Class A common stock dividend for the second quarter of 2025.
RAMACO ANNOUNCES SECOND QUARTER OF 2025 DIVIDEND DETAILS
As previously announced, the Board of Directors approved and declared a quarterly Class A common stock dividend of $0.06875 per share of Class A common stock, payable on June 13, 2025 (the "Payment Date"), to shareholders of record on May 30, 2025 (the "Record Date"), with the dividend to be paid in shares of Class B common stock.
Also as previously announced, Class A common stockholders will receive a number of shares of Class B common stock for each share of Class A common stock determined by dividing $0.06875 by the closing transaction price of the Class B common stock on May 30, 2025, which was $7.45 per share (the "Class B Closing Price").
Based on the Class B Closing Price, each Class A common stockholder will receive 0.009228 of one share of Class B common stock for each share of Class A common stock held by the Class A common stockholder at the close of the market on May 30, 2025.
No fractional shares will be issued in connection with the above-described stock dividend. In lieu of the issuance of fractional shares, the Company will pay in cash on the Payment Date the fair value of the fractions of a share issuable, determined as of the close of Nasdaq on the Record Date and based upon the Class B Closing Price.
For additional information please see our Current Report on Form 8-K which is expected to be filed with the Securities and Exchange Commission later today.
ABOUT RAMACO RESOURCES
Ramaco Resources, Inc. is an operator and developer of high-quality, low-cost metallurgical coal in southern West Virginia, and southwestern Virginia and a developing producer of coal, rare earth and critical minerals in Wyoming. Its executive offices are in Lexington, Kentucky, with operational offices in Charleston, West Virginia and Sheridan, Wyoming. The Company currently has four active metallurgical coal mining complexes in Central Appalachia and one development rare earth and coal mine near Sheridan, Wyoming in the initial stages of production. In 2023, the Company announced that a major deposit of primary magnetic rare earths and critical minerals was discovered at its mine near Sheridan, Wyoming. Contiguous to the Wyoming mine, the Company operates a carbon research and pilot facility related to the production of advanced carbon products and materials from coal. In connection with these activities, it holds a body of roughly 76 intellectual property patents, pending applications, exclusive licensing agreements and various trademarks. News and additional information about Ramaco Resources, including filings with the Securities and Exchange Commission, are available at http://www.ramacoresources.com. For more information, contact investor relations at (859) 244-7455.
POINT OF CONTACT
INVESTOR RELATIONS: info@ramacometc.com or 859-244-7455
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Ramaco Resources' expectations or beliefs concerning guidance, future events, anticipated revenue, future demand and production levels, macroeconomic trends, the development of ongoing projects, costs and expectations regarding operating results, and it is possible that the results described in this news release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Ramaco Resources' control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. These factors include, without limitation, unexpected delays in our current mine development activities, the ability to successfully ramp up production at our complexes in accordance with the Company's growth initiatives, failure of our sales commitment counterparties to perform, increased government regulation of coal in the United States or internationally, the impact of tariffs imposed by the United States and foreign governments, the further decline of demand for coal in export markets and underperformance of the railroads, the Company's ability to successfully develop the Brook Mine, including whether the Company's exploration target and estimates for such mine are realized, the timing of the initial production of rare earth concentrates, the development of a pilot and ultimately a full scale commercial processing facility. Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Ramaco Resources does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Ramaco Resources to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements found in Ramaco Resources' filings with the Securities and Exchange Commission ("SEC"), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The risk factors and other factors noted in Ramaco Resources' SEC filings could cause its actual results to differ materially from those contained in any forward-looking statement.
View original content:https://www.prnewswire.com/news-releases/ramaco-resources-announces-second-quarter-class-a-stock-dividend-details-302470815.html
SOURCE Ramaco Resources, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
UPSHER-SMITH SHOWCASES ITS COMMITMENT TO DUCHENNE MUSCULAR DYSTROPHY COMMUNITY AS A TRUSTED PARTNER IN PEDIATRIC RARE DISEASES AT THE PARENT PROJECT MUSCULAR DYSTROPHY (PPMD) 2025 ANNUAL CONFERENCE
Visit Upsher-Smith at the PPMD 2025 Annual Conference Resource Fair to Learn More About Support Services and Resources Offered for Deflazacort Tablets MAPLE GROVE, Minn., June 16, 2025 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its participation at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference from June 19-21, 2025 in Las Vegas, Nevada. Representatives from Upsher-Smith will be available to share information about Deflazacort Tablets and discuss the Company's intent and commitment to bring its best-in-class rare disease support and services to the Duchenne muscular dystrophy community. "Experience matters in rare disease. Founded in 1919, Upsher-Smith has been serving patients for more than 100 years and has a long-standing commitment to supporting the unique needs of rare disease communities," said Jim Maahs, Head of Commercial, Upsher-Smith. "As a trusted partner in pediatric rare disease, we invite attendees to visit us during this year's PPMD Annual Conference to learn how Upsher-Smith is committing to elevating the standard of support for patients and families affected by Duchenne muscular dystrophy (DMD) by offering high-quality generic treatment options that match or exceed the level of support services provided by innovator brands." About Upsher-Smith's Deflazacort Tablets Deflazacort Tablets from Upsher-Smith are an AB-rated generic version of Emflaza® (deflazacort) Tablets.1 This means they have the same active ingredient in the same strength and dosage form and provide the same efficacy, tolerability, and safety as Emflaza®.1 Deflazacort Tablets are indicated for the treatment of DMD in patients 5 years of age and older. Upsher-Smith's Deflazacort Tablets are available in 6 mg, 18 mg, 30 mg and 36 mg strengths. Deflazacort tablets are manufactured by Upsher-Smith in Minnesota. INDICATION & IMPORTANT SAFETY INFORMATION FOR DEFLAZACORT TABLETS INDICATION DEFLAZACORT TABLETS are a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. IMPORTANT SAFETY INFORMATION Contraindications: DEFLAZACORT TABLETS are contraindicated in patients with a hypersensitivity to deflazacort or any of the inactive ingredients. Warnings & Precautions Alterations in Endocrine Function: Corticosteroids, such as DEFLAZACORT, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving DEFLAZACORT for Cushing's syndrome, hyperglycemia, and adrenal insufficiency after DEFLAZACORT withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events. Acute adrenal insufficiency or "withdrawal syndrome" can occur if corticosteroids are withdrawn abruptly and can be fatal. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. During times of medical stress, corticosteroid dosage may need to be increased. Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal; signs and symptoms of infection may be masked. Monitor for the development of infection and consider DEFLAZACORT withdrawal or dosage reduction as needed. Tell patients and/or caregivers to inform their healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Warn patients who are on corticosteroids who have not had chickenpox or measles to avoid exposure to chickenpox or measles and to alert their healthcare provider immediately if they are exposed. Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure. Dietary salt restriction and potassium supplementation may be necessary. DEFLAZACORT should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Gastrointestinal Perforation: Increased risk of gastrointestinal perforation during corticosteroid use in patients with certain gastrointestinal disorders such as active or latent peptic ulcers, diverticulitis, recent intestinal anastomoses, and inflammatory bowel disease. Signs and symptoms may be masked. Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. Inform patients or caregivers of the potential for behavioral and mood changes. Effects on Bones: The risk of osteoporosis increases with prolonged use of DEFLAZACORT, which can predispose patients to vertebral and long bone fractures. Monitor for decreases in bone density with chronic use of DEFLAZACORT. Encourage patients to seek medical attention if symptoms develop or worsen. Ophthalmic Effects: May include cataract formation, ocular infections, and glaucoma. If treatment with corticosteroids, including DEFLAZACORT, are continued for more than 6 weeks, monitor intraocular pressure. Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting DEFLAZACORT. Serious Skin Rashes: Toxic epidermal necrolysis has been reported with the use of deflazacort. Discontinue at the first sign of rash, unless the rash is clearly not drug related. Effects on Growth and Development: Long-term use of corticosteroids, including DEFLAZACORT, can have negative effects on growth and development in children. Thromboembolic Events: Observational studies have shown an increased risk of thromboembolism. Use DEFLAZACORT with caution in patients who have or may be predisposed to thromboembolic disorders. Adverse Reactions: The most common adverse reactions (≥10% for DEFLAZACORT and greater than placebo) are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis. Drug Interactions: Give one third of the recommended dose of DEFLAZACORT when DEFLAZACORT is administered with strong or moderate CYP3A4 inhibitors. Avoid use of strong or moderate CYP3A4 inducers with DEFLAZACORT, as they may reduce efficacy. This safety information is not comprehensive. Please see the full Prescribing Information for DEFLAZACORT TABLETS. You can also visit or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to Upsher-Smith Laboratories, LLC at 1-888-650-3789 or to the FDA by visiting About Upsher-SmithUpsher-Smith Laboratories, LLC, now a member of Bora Group, is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. We bring generics and brands to a wide array of customers, always backed by our attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit About Bora Founded in 2007, Bora Pharmaceutical Co., Ltd. ("Bora" or "the Company", now is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Bora is dedicated to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency and reliability. For more information, visit Reference: 1. Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book Food and Drug Administration Website. gov/scripts/cder/ob/ Emflaza is a registered trademark of PTC Therapeutics, Inc. View original content to download multimedia: SOURCE Upsher-Smith Laboratories, LLC
Business Wire
38 minutes ago
- Business Wire
Sealy & Company Announces Retirement of CFO and Appointment of Successor
DALLAS--(BUSINESS WIRE)--Sealy & Company ('Sealy'), a leading real estate investment and services firm, today announced the retirement of James Cook, Chief Financial Officer (CFO), after 24 years of dedicated service. Mr. Cook will officially retire on June 30, 2025, and the company is pleased to announce that James Gilligan will succeed Mr. Cook as the new CFO, effective June 16, 2025. Sealy & Company is pleased to announce that James Gilligan will succeed James Cook as the new CFO, effective June 16, 2025, as Mr Cook announces his retirement after 24 years of dedicated service to the firm. Share During Mr. Cook's tenure, Sealy has seen significant growth, including sponsorship of a multi-entity real estate investment program, with combined assets under management in excess of $3 billion. His leadership and financial expertise have been instrumental in scaling and leading the business. 'We are incredibly grateful for James's contributions to Sealy,' said Mark P. Sealy, President of Sealy. 'We are deeply thankful for his exceptional leadership, strategic vision, and commitment to our company's growth and success over the years.' James Gilligan joined the company in April 2025 and brings a robust executive leadership background centered around real estate investments and private equity. Mr. Gilligan was CFO and Treasurer of Farmland Partners (NYSE: FPI) from 2021 to 2024, and before that worked at Equity International and Equity Group Investments, two investment firms founded by Sam Zell. Mr. Gilligan and Mr. Cook have worked closely over the last two months to facilitate knowledge transfer and a seamless handover of responsibilities. About Sealy & Company Sealy & Company, a fully integrated commercial real estate investment, and operating company, is a recognized leader in acquiring, developing, and redeveloping regional distribution warehouse, industrial/flex, and other commercial properties. Sealy provides a full-service platform for high-net-worth individuals and institutional investors through our development, management, and brokerage divisions. Sealy & Company has an exceptional team of over 100 employees, located in five offices, with corporate offices in Dallas, TX and Shreveport, LA.
Yahoo
44 minutes ago
- Yahoo
3 Brutal Truths About Social Security Boomers Must Understand
Retirement planning is serious business — proper and responsible planning can be the difference between ensuring that your golden years are safe and comfortable, or fraught and financially disastrous. A crucial component to that retirement planning? Understanding Social Security. Be Aware: Consider This: That said, the generation currently entering into retirement age — baby boomers — may not have the grasp on the hard realities of Social Security that are needed for a responsible, well-planned retirement. In fact, there are a handful of mistakes and misnomers about Social Security that are easy for boomers to make, if they're not careful. These truths, while potentially frightening, even brutal, have to be understood for a stable retirement. Quite simply, Social Security, while a safety net, cannot be considered a sole source of retirement income. It just isn't enough; Social Security funds were designed to bolster retirement income, not be the only source of it. Boomers must plan for a primary retirement income other than Social Security. Read More: Why should boomers not rely on Social Security only? Per The Motley Fool (via Nasdaq), at best Social Security funds will only cover approximately 40% of a retiring boomer's pre-retirement income. That's 60% of pre-retirement income that has to be found elsewhere, unless you're prepared to lose more than half of one's income, and live on the little that's left. As 24/7 WallStreet has reported, unless Congress takes significant action, it's very possible that the Social Security Administration will run out of funding by 2035 — a time when a vast majority of boomers will be retired and living upon at least some level of Social Security. Not only is Social Security not enough to serve as a sole retirement income, it may not even be solvent within a decade. A hard, brutal truth that all boomers must face is that, despite what they've put into Social Security, it cannot be relied upon to save, or even protect, their retirement. The remedy for this? Savings, investments, responsible spending and a varied portfolio – and a healthy honestly about the sometimes brutal reality surrounding America's Social Security system. More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 4 Affordable Car Brands You Won't Regret Buying in 2025 6 Popular SUVs That Aren't Worth the Cost -- and 6 Affordable Alternatives This article originally appeared on 3 Brutal Truths About Social Security Boomers Must Understand Sign in to access your portfolio
